These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
563 related articles for article (PubMed ID: 15292526)
41. The status of doping and drug use and the implications for boxing. Wadler GI Clin Sports Med; 2009 Oct; 28(4):533-43, v-vi. PubMed ID: 19819400 [TBL] [Abstract][Full Text] [Related]
42. Overview of the legal framework applicable to the marker method for the detection of human growth hormone. Young RR; Bielak JS; Horvitz SL Growth Horm IGF Res; 2009 Aug; 19(4):366-8. PubMed ID: 19608446 [TBL] [Abstract][Full Text] [Related]
43. Therapeutic use exemptions (TUEs) at the Olympic Games 1992-2012. Fitch KD Br J Sports Med; 2013 Sep; 47(13):815-8. PubMed ID: 23591601 [TBL] [Abstract][Full Text] [Related]
44. A third generation approach to detect erythropoietin abuse in athletes. Sharpe K; Ashenden MJ; Schumacher YO Haematologica; 2006 Mar; 91(3):356-63. PubMed ID: 16503554 [TBL] [Abstract][Full Text] [Related]
45. Athletes' knowledge and views on OTC medication. Mottram D; Chester N; Atkinson G; Goode D Int J Sports Med; 2008 Oct; 29(10):851-5. PubMed ID: 18401811 [TBL] [Abstract][Full Text] [Related]
46. Medication use by athletes at the Athens 2004 Summer Olympic Games. Tsitsimpikou C; Tsiokanos A; Tsarouhas K; Schamasch P; Fitch KD; Valasiadis D; Jamurtas A Clin J Sport Med; 2009 Jan; 19(1):33-8. PubMed ID: 19124981 [TBL] [Abstract][Full Text] [Related]
47. Antidoping program: an important factor in the promotion and protection of the integrity of sport and athlete's health. Mazzeo F; Monda V; Santamaria S; Nigro E; Valenzano A; Villano I; Cibelli G; Messina A; Messina G J Sports Med Phys Fitness; 2018; 58(7-8):1135-1145. PubMed ID: 28738670 [TBL] [Abstract][Full Text] [Related]
48. Abuse of medicines for performance enhancement in sport: why is this a problem for the pharmaceutical industry? Elliott S; Leishman B Bioanalysis; 2012 Jul; 4(13):1681-90. PubMed ID: 22831483 [TBL] [Abstract][Full Text] [Related]
49. Structure and Development of the List of Prohibited Substances and Methods. Kinahan A; Budgett R; Mazzoni I Med Sport Sci; 2017; 62():39-54. PubMed ID: 28571027 [TBL] [Abstract][Full Text] [Related]
50. Analytical progresses of the International Olympic Committee and World Anti-Doping Agency Olympic laboratories. Georgakopoulos C; Saugy M; Giraud S; Robinson N; Alsayrafi M Bioanalysis; 2012 Jul; 4(13):1549-63. PubMed ID: 22831472 [TBL] [Abstract][Full Text] [Related]
51. Protein chips for high-throughput doping screening in athletes. Du H; Cheng J Expert Rev Proteomics; 2006 Feb; 3(1):111-4. PubMed ID: 16445355 [TBL] [Abstract][Full Text] [Related]
52. Arrhythmogenic effects of illicit drugs in athletes. Furlanello F; Bentivegna S; Cappato R; De Ambroggi L Ital Heart J; 2003 Dec; 4(12):829-37. PubMed ID: 14976846 [TBL] [Abstract][Full Text] [Related]
53. Practical experience with the implementation of an athlete's biological profile in athletics, cycling, football and swimming. Zorzoli M; Pipe A; Garnier PY; Vouillamoz M; Dvorak J Br J Sports Med; 2014 May; 48(10):862-6. PubMed ID: 24648438 [TBL] [Abstract][Full Text] [Related]
54. [The fight against doping: today and tomorrow]. Rieu M Bull Acad Natl Med; 2004; 188(6):955-71; discussion 972. PubMed ID: 15651425 [TBL] [Abstract][Full Text] [Related]
55. Pharmaceutical services at the Tenth Pan American Games. Wagner JC; Ulrich LR; McKean DC; Blankenbaker RG Am J Hosp Pharm; 1989 Oct; 46(10):2023-7. PubMed ID: 2479267 [TBL] [Abstract][Full Text] [Related]